Halozyme Therapeutics reported better-than-expected Q1 2026 earnings, reaffirmed its 2026–2028 guidance, and announced a new $1 billion share repurchase program. The company continues to generate strong royalty revenue growth and maintains high gross margins above 75%, supporting strong free cash flow. Despite these strengths, Halozyme shares trade at a notable discount compared to historical and sector valuations. The analyst values the stock at $74.30 per share, citing its double-digit royalty growth, high capital returns, and a promising product pipeline as key drivers of shareholder value.
Li Auto has integrated Arteris' FlexNoC 5 network-on-chip IP and Magillem software into its proprietary autonomous driving SoCs for the new L9 Livis SUV. This technology supports AI data movement and integration, enabling the vehicle to perform 2,560...
Arteris, Inc. announced its system IP technology is adopted by Li Auto for its new L9 Livis flagship SUV, integrating the Mach M100 autonomous driving SoC. This collaboration enhances AI data movement and system efficiency, meeting high performance, ...
Durantic, founded by former Meta and Hudson River Trading engineers, has launched a managed infrastructure layer to operate AI workloads across diverse GPU environments. The company addresses the growing complexity of AI infrastructure, which spans h...
Disc Medicine, Inc. is facing a class action lawsuit after the FDA issued a Complete Response Letter rejecting its new drug application for bitopertin due to uncertainties requiring more evidence. This announcement caused the company's stock to fall ...
ServiceNow reported strong Q1 results with 22% subscription revenue growth and 97% customer retention, raising its full-year guidance. Despite these robust fundamentals and a clear AI-driven growth strategy targeting $1.5 billion in annual contract v...
